

MEETING ABSTRACT

Open Access

# Electrophysiological effects of rosiglitazone on heart ventricular papillary muscles of control and diabetic histidine decarboxylase knock-out and wild-type mice

Andrea Szebeni\*, Ágnes Kovács, Valéria Kecskeméti

From 17th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the Hungarian Society of Experimental and Clinical Pharmacology (MFT) Innsbruck, Austria. 29-30 September 2011

## Background

Rosiglitazone is a thiazolidinedione derivative oral hypoglycemic agent active in both diabetic animal models and type 2 diabetic patients. Rosiglitazone is a high affinity ligand for the peroxisome proliferator-activated receptor gamma, which is responsible for the insulin-sensitizing action of the compound. Recent large clinical trials found an association between the antidiabetic drug rosiglitazone therapy and increased risk of cardiovascular adverse events.

## Methods

The aim of this report is to elucidate the cardiac electrophysiological properties of rosiglitazone on control and diabetic murine ventricular papillary muscles using conventional microelectrode technique.

## Results

In control histidine-decarboxylase knock-out mice (HDC-KO) as well as in their wild-types (WT) rosiglitazone (1–30 μM) shortened AP duration at the 90% level of repolarization (APD<sub>90</sub>) and increased the AP amplitude (APA) in a concentration-dependent manner. Moreover, rosiglitazone reduced the maximum velocity of depolarization ( $V_{max}$ ). In diabetic animals we detected very similar effects.

## Conclusions

The action potential changes caused by rosiglitazone probably can be explained by ion channel effects. The observed alterations may carry a serious proarrhythmic risk in case of overdose intoxication with rosiglitazone, especially in patients having multiple cardiovascular risk factors, like elderly diabetic patients.

Published: 5 September 2011

doi:10.1186/1471-2210-11-S2-A53

Cite this article as: Szebeni et al.: Electrophysiological effects of rosiglitazone on heart ventricular papillary muscles of control and diabetic histidine decarboxylase knock-out and wild-type mice. *BMC Pharmacology* 2011 11(Suppl 2):A53.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



\* Correspondence: [szeband@pharma.sote.hu](mailto:szeband@pharma.sote.hu)

Department of Pharmacology and Pharmacotherapy, Semmelweis University,  
1089 Budapest, Hungary